Not Signed In -
Ethosuximide Capsules |
Zarontin |
Clinical Trial: An Open-Label Extension to Evaluate the Efficacy and Safety of Rivastigmine Capsules in Patients with Probable Vascular Dementia
This study is no longer recruiting patients.
|
Purpose
The goal of this research study is to evaluate, in the open-label extension phase, the effectiveness, tolerability and safety of rivastigmine capsules in males and females between the ages of 50 and 85 years old with probable vascular dementia.
| Condition | Intervention | Phase |
|---|---|---|
| Vascular Dementia | Drug: Rivastigmine | Phase III |
MedlinePlus related topics: Dementia; Stroke; Vascular Diseases
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Further Study Details:
Study start: February 2002
Eligibility
Ages Eligible for Study: 50 Years - 85 Years, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
- Patients who complete the double-blind treatment phase or those who have dropped out early in the study, but have returned for all the remaining scheduled efficacy assessments (retrieved drop-out patients) without significant protocol violations are eligible to participate.
Exclusion Criteria:
- Retrieved drop-out patients, who have been treated with other cholinergic drugs during the past 4 weeks
More Information
Study ID Numbers: CENA713 IA05E1
Last Updated: August 12, 2005
Record first received: August 11, 2005
ClinicalTrials.gov Identifier: NCT00130338
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-08-23
Last Updated: August 12, 2005
Record first received: August 11, 2005
ClinicalTrials.gov Identifier: NCT00130338
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-08-23
Resources
- Ethosuximide Capsules (Drug Digest)
- Zarontin (Drug Digest)
email this page
print this page
bookmark this page
feedback on this page
